Literature DB >> 2491865

Functional hypersomatotropism in small for gestational age (SGA) newborn infants.

M Deiber1, P Chatelain, D Naville, G Putet, B Salle.   

Abstract

Basal plasma GH levels and the GH responses to an injection of 1 microgram/kg 1-44(NH2) GHRH were determined on day 3 postnatally in 5 small gestational age (SGA) twin newborns and their appropriate gestational age (AGA) co-twins, and in 10 SGA singleton newborns and 6 AGA singleton newborns. The mean basal plasma GH level was higher in the SGA than in the AGA infants but the difference was significant only for singleton newborns (p less than 0.01). The mean peak plasma GH level was markedly increased in SGA compared to AGA infants (p less than 0.05 for twins, p less than 0.01 for singletons). Twelve SGA infants re-tested at 1 month had lower basal and peak plasma GH levels (p less than 0.001 and p less than 0.01). In 21 SGA and 17 AGA infants, serum IGF-I, measured by RIA between 12 and 96 hours after birth, was significantly higher in SGA than in AGA (p less than 0.001). These results suggest that, whatever the mechanism, functional hypersomatotropism is present at day 3 in SGA infants. This hypersomatotropism may participate in the early catch-up growth process.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2491865     DOI: 10.1210/jcem-68-1-232

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Fetal origins of adult disease: a paediatric perspective.

Authors:  Harriet L Miles; Paul L Hofman; Wayne S Cutfield
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

Review 2.  The Auxological and Metabolic Consequences for Children Born Small for Gestational Age.

Authors:  Wayne Cutfield; Ahila Ayyavoo
Journal:  Indian J Pediatr       Date:  2021-08-17       Impact factor: 1.967

Review 3.  Should recombinant human growth hormone therapy be used in short small for gestational age children?

Authors:  L B Johnston; M O Savage
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

Review 4.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

5.  Size at birth and plasma insulin-like growth factor-1 concentrations.

Authors:  C H Fall; A N Pandit; C M Law; C S Yajnik; P M Clark; B Breier; C Osmond; A W Shiell; P D Gluckman; D J Barker
Journal:  Arch Dis Child       Date:  1995-10       Impact factor: 3.791

Review 6.  The Role of Cellular Stress in Intrauterine Growth Restriction and Postnatal Dysmetabolism.

Authors:  Shelby L Oke; Daniel B Hardy
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

7.  Maternal BMI, IGF-I Levels, and Birth Weight in African American and White Infants.

Authors:  Adriana C Vidal; Amy P Murtha; Susan K Murphy; Kimberly Fortner; Francine Overcash; Nikki Henry; Joellen M Schildkraut; Michele R Forman; Wendy Demark-Wahnefried; Joanne Kurtzberg; Randy Jirtle; Cathrine Hoyo
Journal:  Int J Pediatr       Date:  2013-06-03

8.  Models predicting the growth response to growth hormone treatment in short children independent of GH status, birth size and gestational age.

Authors:  Jovanna Dahlgren; Berit Kriström; Aimon Niklasson; Andreas F M Nierop; Sten Rosberg; Kerstin Albertsson-Wikland
Journal:  BMC Med Inform Decis Mak       Date:  2007-12-12       Impact factor: 2.796

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.